Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with chronic kidney disease: meta-analysis of phase 3 randomized controlled trials
Clinical Kidney Journal · 04.01.2024 · 17 (1)
DOI: 10.1093/ckj/sfad143 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Clinical Kidney Journal, online erschienen am 22.06.2023. Verfasst von Roberto Minutolo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Unit, University of Campania "Luigi Vanvitelli", Naples, Italy. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are new therapeutic agents for anaemia in chronic kidney disease (CKD). We evaluated by meta-analysis and meta-regression the efficacy and safety of HIF-PHIs in patients with CKD-related anaemia.
Methods
We selected phase 3 randomized clinical trials (RCTs) comparing HIF-PHIs and erythropoiesis-stimulating agents (ESAs) in dialysis and non-dialysis patients. Efficacy outcomes were the changes from baseline of haemoglobin, iron parameters (hepcidin, serum iron, TIBC, TSAT, ferritin) and intravenous iron dose; as safety outcomes we considered cancer, adjudicated major adverse cardiovascular events (MACE), MACE+ (MACE plus hospitalization for hearth failure or unstable angina or thromboembolic event), thrombotic events (deep vein thrombosis, pulmonary embolism), arterovenous fistula (AVF) thrombosis and death.
Results
We included 26 RCTs with 24 387 patients. Random effect meta-analysis of the unstandardized mean difference between HIF-PHIs and ESAs showed a significant change in haemoglobin levels from baseline of 0.10 g/dL (95% CI 0.02 to 0.17). Meta-regression analysis showed a significantly higher haemoglobin change for HIF-PHIs in younger patients and versus short-acting ESA (0.21 g/dL, 95% CI 0.12 to 0.29 versus –0.01, 95% CI –0.09 to 0.07 in studies using long-acting ESA, P < .001). No significant effect on heterogeneity was found for type of HIF-PHIs. In comparison with ESAs, HIF-PHIs induced a significant decline in hepcidin and ferritin and a significant increase in serum iron and TIBC, while TSAT did not change; intravenous iron dose was lower with HIF-PHI (–3.1 mg/week, 95% CI –5.6 to –0.6, P = .020). Rate ratio of cancer (0.93, 95% CI 0.76 to 1.13), MACE (1.00, 95% CI 0.94 to 1.07), MACE+ (1.01, 95% CI 0.95 to 1.06), thrombotic events (1.08, 95% CI 0.84 to 1.38), AVF thrombosis (1.02, 95% CI 0.93 to 1.13) and death (1.02, 95% CI 0.95 to 1.13) did not differ between HIF-PHIs and ESAs.
Conclusions
HIF-PHIs at the doses selected for the comparisons are effective in correcting anaemia in comparison with ESA therapy with a significant impact on iron metabolism without notable difference among various agents. No safety signals emerge with use of HIF-PHIs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nephrology Unit, University of Campania "Luigi Vanvitelli", Naples, Italy.
- Medical Statistic Unit, University of Campania "Luigi Vanvitelli", Naples, Italy.
- Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
ORCID-Profile: Roberto Minutolo, Luca De Nicola
Zitieren
APA
Minutolo, R., Liberti, M. E., Simeon, V., Sasso, F. C., Borrelli, S., De Nicola, L., & Garofalo, C. (2024). Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with chronic kidney disease: meta-analysis of phase 3 randomized controlled trials. Clinical Kidney Journal, 17(1). https://doi.org/10.1093/ckj/sfad143
Vancouver
Minutolo R, Liberti ME, Simeon V, Sasso FC, Borrelli S, De Nicola L, et al. Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with chronic kidney disease: meta-analysis of phase 3 randomized controlled trials. Clinical Kidney Journal. 2024;17(1). doi:10.1093/ckj/sfad143
BibTeX
@article{Minutolo2024,
author = {Minutolo, Roberto and Liberti, Maria Elena and Simeon, Vittorio and Sasso, Ferdinando C and Borrelli, Silvio and De Nicola, Luca and Garofalo, Carlo},
title = {Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with chronic kidney disease: meta-analysis of phase 3 randomized controlled trials},
journal = {Clinical Kidney Journal},
year = {2024},
volume = {17},
number = {1},
doi = {10.1093/ckj/sfad143}
}
EUVIMED